American clinical stage biotechnology company at Waltham in Massachusetts, founded in 2018 and listed on Nasdaq. Develops targeted nucleic acid medicines for genetically driven muscle diseases using its FORCE platform, which links oligonucleotides to an antibody fragment against the transferrin receptor 1 to deliver them into muscle, with clinical programmes in myotonic dystrophy type 1 and Duchenne muscular dystrophy and preclinical work in facioscapulohumeral dystrophy and other rare muscle disorders.
Aucun commentaire disponible.
Laissez votre note & commentaire